Selexipag: all 25 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3
• A Study of Selexipag in Participants Who Participated in a Previous Selexipag StudyCompletedNCT04565990Phase 3Results posted
• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedNCT04435782Phase 4Results posted
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT04175600Phase 3Results posted
• A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral SelexipagTerminatedNCT03942211Phase 2Results posted
• A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional TreatmentTerminatedNCT03689244Phase 3Results posted
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT03492177Phase 2Results posted
• Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial HypertensionCompletedNCT03187678Phase 3Results posted
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedNCT03078907Phase 4Results posted
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedNCT02558231Phase 3Results posted
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial HypertensionCompletedNCT02471183Phase 3Results posted
• ACT-293987 in Pulmonary Arterial HypertensionCompletedNCT01112306Phase 3Results posted
• Selexipag (ACT-293987) in Pulmonary Arterial HypertensionCompletedNCT01106014Phase 3Results posted
• Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated TabletsCompletedNCT07694128Phase 1
• Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)CompletedNCT06932198Phase 1
• Pulmonary Hypertension: Intensification and Personalisation of Combination RxActive, not recruitingNCT05825417Phase 4
• Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial HypertensionStatus unknownNCT04589390Phase 2
• A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male SubjectsCompletedNCT03496506Phase 1
• Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy SubjectsCompletedNCT02882425Phase 1
• Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male SubjectsCompletedNCT02791815Phase 1
• A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy SubjectsCompletedNCT02770222Phase 1
• Comparison of Two Dose Strengths of Selexipag in Healthy AdultsCompletedNCT02745860Phase 1
• Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT02260557Phase 2
• Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μgCompletedNCT02206295Phase 1
• Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female SubjectsCompletedNCT02206204Phase 1

← Selexipag overview